FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214022906> ?p ?o ?g. }

• W3214022906 endingPage "A188" @default.
• W3214022906 startingPage "A188" @default.
• W3214022906 abstract "Background Patients with RCC may achieve remission with immune-checkpoint inhibitors (ICI); however, most patients will progress. Adoptive cell therapy with autologous TIL allows for expansion of T-cells from tumor tissue leading to a polyclonal T-cell product with a diverse T-cell receptor repertoire capable of recognizing an array of tumor antigens. TIL therapy with centrally manufactured lifileucel demonstrated a 36% overall response rate in patients with ICI-refractory melanoma. 1 We present our preclinical experience of TIL production in RCC. Methods This study was approved by the DF/HCC Institutional Review Board. Fresh tumor samples (≥1.5-cm) were harvested from consented patients undergoing resection for RCC. TIL were manufactured using pre-rapid expansion (1/10th scale) and rapid expansion (1/100th scale) protocol for 22 days. Characterization (total viable cells [TVC],% viability, identity, and potency) was performed on the final TIL product. TIL purity, differentiation, memory, activation, and exhaustion status were characterized using multi-color flow cytometry. Results Baseline characteristics of 11 recruited patients are shown in table 1. Clear cell was the most common histology (73%). Two patients had previously treated metastatic disease with samples harvested from the lung and adrenal gland; one patient had prior cryoablation with adjacent local recurrence. The remainder were treatment-naïve primary nephrectomy samples. Eight products (73%) showed acceptable TIL product attributes (table 2). Median (range) TVC, viability, and identity (CD45+CD3+%) for the final TIL product were 74×109 (18×109–133×109), 95% (86%–97%), and 98% (94%–99%), respectively. Median (range) percentage of CD4+ cells was 69% (21%–97%) and CD8+ cells was 27% (2%–72%). The non–T-cell population, including B cells, monocytes, and NK cells, was <7%. The final TIL product was functional, and responded to polyclonal bead stimulation; the median (range) IFNg and granzyme B were 8834 (3319–12,957) pg/mL and 34,329 (15,565–65,521) pg/mL, respectively. Acceptable TIL product was generated from both metastatic lesions and primary tumor samples. Of the 3 tumor samples that did not demonstrate acceptable TIL product attributes, one (ID 1) was from a patient treated with a CXCR4 inhibitor <1 month before resection, another (ID 4) was from a patient previously treated with ocrelizumab (CD20-directed cytolytic antibody) for multiple sclerosis, and the final (ID 8) was harvested from the cryoablated tumor nodule rather than the adjacent recurrent tumor. Abstract 176 Table 1 Baseline demographics and tumor characteristics Abstract 176 Table 2 Summary of product attributes. 1, No CD3+ subset. 2, Product not available to test Conclusions These feasibility data suggest that TIL can be successfully expanded ex vivo from RCC samples (including pre-treated and metastatic tumors) and support potential clinical investigation of TIL in patients with RCC. References Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol 2021 May 12 :JCO2100612. doi: 10.1200/JCO.21.00612. Epub ahead of print. PMID: 33979178. Ethics Approval This study was approved by the DF/HCC Institutional Review Board protocol # 06-105." @default.
• W3214022906 created "2021-11-22" @default.
• W3214022906 creator A5001781079 @default.
• W3214022906 creator A5007052233 @default.
• W3214022906 creator A5021781935 @default.
• W3214022906 creator A5024381064 @default.
• W3214022906 creator A5025137142 @default.
• W3214022906 creator A5031890333 @default.
• W3214022906 creator A5035642271 @default.
• W3214022906 creator A5036619715 @default.
• W3214022906 creator A5067674096 @default.
• W3214022906 creator A5071480455 @default.
• W3214022906 creator A5075341961 @default.
• W3214022906 creator A5081174035 @default.
• W3214022906 creator A5082375304 @default.
• W3214022906 date "2021-11-01" @default.
• W3214022906 modified "2023-10-18" @default.
• W3214022906 title "176 Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy" @default.
• W3214022906 doi "https://doi.org/10.1136/jitc-2021-sitc2021.176" @default.
• W3214022906 hasPublicationYear "2021" @default.
• W3214022906 type Work @default.
• W3214022906 sameAs 3214022906 @default.
• W3214022906 citedByCount "1" @default.
• W3214022906 countsByYear W32140229062023 @default.
• W3214022906 crossrefType "journal-article" @default.
• W3214022906 hasAuthorship W3214022906A5001781079 @default.
• W3214022906 hasAuthorship W3214022906A5007052233 @default.
• W3214022906 hasAuthorship W3214022906A5021781935 @default.
• W3214022906 hasAuthorship W3214022906A5024381064 @default.
• W3214022906 hasAuthorship W3214022906A5025137142 @default.
• W3214022906 hasAuthorship W3214022906A5031890333 @default.
• W3214022906 hasAuthorship W3214022906A5035642271 @default.
• W3214022906 hasAuthorship W3214022906A5036619715 @default.
• W3214022906 hasAuthorship W3214022906A5067674096 @default.
• W3214022906 hasAuthorship W3214022906A5071480455 @default.
• W3214022906 hasAuthorship W3214022906A5075341961 @default.
• W3214022906 hasAuthorship W3214022906A5081174035 @default.
• W3214022906 hasAuthorship W3214022906A5082375304 @default.
• W3214022906 hasBestOaLocation W32140229061 @default.
• W3214022906 hasConcept C121608353 @default.
• W3214022906 hasConcept C126322002 @default.
• W3214022906 hasConcept C143998085 @default.
• W3214022906 hasConcept C2777472916 @default.
• W3214022906 hasConcept C2777628079 @default.
• W3214022906 hasConcept C2777701055 @default.
• W3214022906 hasConcept C2778326572 @default.
• W3214022906 hasConcept C2778560582 @default.
• W3214022906 hasConcept C2778902805 @default.
• W3214022906 hasConcept C2780091579 @default.
• W3214022906 hasConcept C2780227381 @default.
• W3214022906 hasConcept C71924100 @default.
• W3214022906 hasConceptScore W3214022906C121608353 @default.
• W3214022906 hasConceptScore W3214022906C126322002 @default.
• W3214022906 hasConceptScore W3214022906C143998085 @default.
• W3214022906 hasConceptScore W3214022906C2777472916 @default.
• W3214022906 hasConceptScore W3214022906C2777628079 @default.
• W3214022906 hasConceptScore W3214022906C2777701055 @default.
• W3214022906 hasConceptScore W3214022906C2778326572 @default.
• W3214022906 hasConceptScore W3214022906C2778560582 @default.
• W3214022906 hasConceptScore W3214022906C2778902805 @default.
• W3214022906 hasConceptScore W3214022906C2780091579 @default.
• W3214022906 hasConceptScore W3214022906C2780227381 @default.
• W3214022906 hasConceptScore W3214022906C71924100 @default.
• W3214022906 hasIssue "Suppl 2" @default.
• W3214022906 hasLocation W32140229061 @default.
• W3214022906 hasLocation W32140229062 @default.
• W3214022906 hasOpenAccess W3214022906 @default.
• W3214022906 hasPrimaryLocation W32140229061 @default.
• W3214022906 hasRelatedWork W2024745271 @default.
• W3214022906 hasRelatedWork W2045947905 @default.
• W3214022906 hasRelatedWork W2064584213 @default.
• W3214022906 hasRelatedWork W2069686259 @default.
• W3214022906 hasRelatedWork W2410239163 @default.
• W3214022906 hasRelatedWork W2416853546 @default.
• W3214022906 hasRelatedWork W2616971337 @default.
• W3214022906 hasRelatedWork W2921739520 @default.
• W3214022906 hasRelatedWork W2964854407 @default.
• W3214022906 hasRelatedWork W3105255196 @default.
• W3214022906 hasVolume "9" @default.
• W3214022906 isParatext "false" @default.
• W3214022906 isRetracted "false" @default.
• W3214022906 magId "3214022906" @default.
• W3214022906 workType "article" @default.